Figure 2.

Effects of cordycepin and/or cisplatin on cell viability in HNSCC cell lines.

Notes: Cells (1 × 10⁴ cells/well for OC3 and OEC-M1; 8 × 10³ cells/well for FaDu) were treated with plain medium, medium with DMSO (0.5%), cordycepin alone (10 μM, 100 μM, and 1 mM), cisplatin alone (100 μM, 300 μM, 600 μM, and 1 mM) or cotreatment with cordycepin (100 μM) plus cisplatin (300 and 600 μM, respectively) for 24 hours ([A] OC3; [B] OEC-M1; and [C] FaDu). Cell viability was quantified by MTT assay. Results are expressed as percentages of cell growth relative to the initial number of viable cells in controls (as 100%). Data represent the mean ± standard error of the mean of three separate experiments. Significant difference from the control (plain medium) (P<0.05).

Abbreviations: DMSO, dimethyltetrazolium bromide; HNSCC, head and neck squamous cell carcinoma; MTT, methylthiazoletetrazolium.